Susquehanna International Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-14,600
Closed -$71K 11422
2020
Q1
$71K Sell
14,600
-100
-0.7% -$648 ﹤0.01% 9515
2019
Q4
$156K Sell
14,700
-58,100
-80% -$577K ﹤0.01% 8927
2019
Q3
$758K Sell
72,800
-35,700
-33% -$467K ﹤0.01% 6329
2019
Q2
$1.66M Sell
108,500
-24,800
-19% -$359K ﹤0.01% 4541
2019
Q1
$1.71M Sell
133,300
-69,600
-34% -$787K ﹤0.01% 3998
2018
Q4
$1.93M Buy
202,900
+3,800
+2% +$49.3K ﹤0.01% 3578
2018
Q3
$3.31M Buy
199,100
+30,200
+18% +$484K ﹤0.01% 3223
2018
Q2
$2.71M Buy
168,900
+86,000
+104% +$1.54M ﹤0.01% 3524
2018
Q1
$1.27M Buy
82,900
+50,900
+159% +$794K ﹤0.01% 4752
2017
Q4
$499K Sell
32,000
-20,700
-39% -$277K ﹤0.01% 6649
2017
Q3
$585K Buy
52,700
+36,500
+225% +$343K ﹤0.01% 6255
2017
Q2
$149K Sell
16,200
-41,100
-72% -$343K ﹤0.01% 8501
2017
Q1
$490K Buy
57,300
+28,000
+96% +$255K ﹤0.01% 6522
2016
Q4
$314K Buy
29,300
+13,600
+87% +$164K ﹤0.01% 7897
2016
Q3
$170K Buy
+15,700
New +$128K ﹤0.01% 7699
2016
Q2
Sell
-12,200
Closed -$57K 9661
2016
Q1
$57K Buy
+12,200
New +$59.6K ﹤0.01% 8631
2015
Q4
Sell
-45,100
Closed -$398K 10235
2015
Q3
$398K Buy
+45,100
New +$473K ﹤0.01% 7557
2014
Q4
Sell
-16,000
Closed -$199K 10303
2014
Q3
$199K Buy
+16,000
New +$197K ﹤0.01% 8688

Susquehanna International Group's STML Position: Q2 2020 in Review

Susquehanna International Group sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 59,168 shares — an estimated $286K sold.

Susquehanna International Group first reported a position in STML in Q4 2013 and held it in 19 quarters. The position peaked at $1.85M in Q4 2018. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • Susquehanna International Group reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Susquehanna International Group sold 59,168 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $286K.
  • Susquehanna International Group first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 19 quarters.
  • Susquehanna International Group's Stemline Therapeutics, Inc. position peaked at $1.85M in Q4 2018.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Susquehanna International Group's 13F filing for Q2 2020, filed 14 Aug 2020.